Abstract Details

Title Effects of HIV Clade B and C on Brain Volumetric Measurements

Topic Infections/AIDS/Prion Disease

Presentation(s) P06 - (-)

Poster/Presentation
Number 177

Objective

Background BACKGROUND: HIV type 1 has genetic subtypes (clades) with varying prevalence throughout the world. [1] Previous in-vitro and animal research studies that have compared HIV-1B and HIV-1C have suggested that HIV-1B may be more neurovirulent than HIV-1C. While recent clinical studies have shown that a high frequency of cognitive impairment is evident in both clades, no studies have directly compared brain volumetric indices.

Design/Methods DESIGN/METHODS: 68 age- and education-matched participants (17 HIV-1C combination anti-retroviral therapy (cART) naive, 17 HIV-1B cART naive, and 17 HIV-negative controls from each region) were recruited from the US (HIV-1B) and South Africa (HIV-1C). All subjects underwent laboratory studies, and neuroimaging performed on Siemens 3T scanners with identical sequence parameters. Nine a priori volumetric regions were analyzed from Freesurfer v5.1; (caudate, thalamus, hippocampus, corpus callosum, putamen, grey and white matter, total ventricular volume and amygdala). The impact of clade was evaluated by the interaction term in a factorial two-way ANOVA with HIV status and group (clade) as factors. Additionally, lower HIV-1C counts are associated with smaller caudate volume.

Results RESULTS: HIV infected (HIV+) individuals in general had smaller volumes in thalamus and global grey matter, compared to HIV- controls. HIV-1C and HIV-1B individuals displayed a similar degree of atrophy compared to HIV- controls within the various regions analyzed. When accounting for duration of infection, HIV-1C had a larger amount of atrophy in total grey matter (2.7% greater loss in HIV-1C than HIV-1B; p= .02).

Conclusions CONCLUSIONS: Although in-vitro studies suggest HIV-1B may be more neurotoxic, we did not see the same trend in our clade B to clade C comparison. Future longitudinal studies are required to assess the effects of cART on volumetric measures within these clades.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Beau M. Ances, MD, PhD, MS, F�鶹��ýӳ�� (Washington University in Saint Louis)	Dr. Ances has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH.
Aaron E. Miller, MD, F�鶹��ýӳ�� (Mt Sinai School Of Med)	Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health Services (Caremark). Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corevitas (formerly known as Corrona). Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI=Pharma. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Viatris (Mylan). Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen (Horizon Therapeutics). Dr. Miller has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Sterne Kessler. Dr. Miller has received publishing royalties from a publication relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��